RE:RE:RE:PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025Pelareorep's life cycle managment is to first to pair pelareorep + with an IV immune checkpoint inhibitor, thus bestowing pelareorep's 13 years of exclusivity on to the IV ICI (which are about to lose their patent protection in 2028) and then subsequently partner pelareorep with an SC ICI, which will gain an original molecule patent extension, based on the new SC route of administration, thus passing that patent extenstion protection on to pelareorep through registering the the pelareorep + ICI SC combination as an exclusive combination treatment.